中大機構典藏-NCU Institutional Repository-提供博碩士論文、考古題、期刊論文、研究計畫等下載:Item 987654321/92750
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 80990/80990 (100%)
Visitors : 41639470      Online Users : 1285
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.lib.ncu.edu.tw/handle/987654321/92750


    Title: 根據效用函數建立複合藥之早期臨床試驗設計;Design of early clinical trial for combined drugs based on utility function
    Authors: 施業娟;SHIH, YEH-CHUAN
    Contributors: 統計研究所
    Keywords: 複合藥;最佳生物劑量組合;早期臨床試驗設計;貝氏方法;模型輔助設計;Combined drugs;Optimal dose combination;Early clinical trial design;Bayesian method;Model-assisted design
    Date: 2023-07-05
    Issue Date: 2024-09-19 16:16:42 (UTC+8)
    Publisher: 國立中央大學
    Abstract: 本文針對合併兩種藥物治療腫瘤的複合藥進行早期臨床試驗設計,其中可能包含二種化療藥或一種化療藥與一種標靶藥。上述複合藥的毒性會因劑量增加而增強,但是標靶藥的遞增藥效可能在較高的劑量時趨於平穩而呈現高原現象,因此本文建議整合毒性與藥效機率設立效用函數,然後尋找該複合藥合乎毒性要求且具有最高效用的最佳生物劑量組合。本文針對二元毒性與藥效反應提出兩種早期臨床試驗設計,其中一種屬於同時考量毒性與藥效的單階升降劑量設計 (cBOIN12);另一種則為兩階段的升降劑量設計(cUBOIN)。最後本文在多種不同的毒性與藥效機率組合情境之下進行模擬,研究上述複合藥早期臨床試驗設計在選擇最佳生物劑量組合的表現與毒性控管的成效,同時也審視兩種設計的試驗時間。;This thesis considers early clinical trial designs for the combination of two drugs in the treatment of oncology, which may include two chemotherapies or a chemotherapy along with a Molecularly Targeted Agent (MTA). The toxicity of the combined drugs increases with higher doses, but the efficacy of the MTA may plateau at higher doses. Therefore, in this thesis, a utility function that integrates the toxicity and efficacy probabilities is used to find the optimal dose combination (ODC) of the combined drugs, where the ODC meets the toxicity requirements and has the largest utility. Two early clinical trial designs are proposed for binary toxicity and efficacy responses, including a single-stage dose-escalation design (cBOIN12) that considers both toxicity and efficacy simultaneously, and a two-stage dose-escalation design (cUBOIN). Finally, we conduct a simulation study under various combinations of toxicity and efficacy probabilities to investigate the performance of estimating ODC and controlling toxicity as well as the required trial time of the proposed early clinical trial designs for combined drugs.
    Appears in Collections:[Graduate Institute of Statistics] Electronic Thesis & Dissertation

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML15View/Open


    All items in NCUIR are protected by copyright, with all rights reserved.

    社群 sharing

    ::: Copyright National Central University. | 國立中央大學圖書館版權所有 | 收藏本站 | 設為首頁 | 最佳瀏覽畫面: 1024*768 | 建站日期:8-24-2009 :::
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 隱私權政策聲明